Exelixis Announces FDA Extends NDA Review for Zanzalintinib

What Happened

• Exelixis, Inc. announced on September 10, 2026 that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months.
• The FDA deemed materials Exelixis submitted in response to an information request—updated safety and efficacy data—a "major amendment." The updated Prescription Drug User Fee Act (PDUFA) action date is March 3, 2027.

Key Details

• FDA notification date: September 10, 2026.
• Extension length: 3 months.
• New PDUFA (action) date: March 3, 2027.
• Reason: Exelixis submitted updated safety and efficacy data; FDA classified it as a major amendment.

Why It Matters

• For investors, the three-month extension moves the expected regulatory decision and potential commercialization timeline for zanzalintinib + atezolizumab into early March 2027, which can affect revenue timing and valuation assumptions.
• The designation of the submission as a major amendment indicates the FDA requested substantive updated data; while not a rejection, it formalizes additional review work by the agency and regulatory risk remains until a decision is issued.